Biotechnology News

Paradigm Biopharma completes enrolment in pivotal Phase 3 osteoarthritis trial

Welcome to HotCopper’s latest Watchlist, where we’ve this week been joined by Paradigm Biopharmaceuticals (ASX:PAR) managing director Paul Rennie to talk about what’s next after the company just cracked another @major milestone&CloseCurlyDoubleQuote...

Isaac McIntyre

4 days ago

ASX News The Watchlist Healthcare Biotechnology

Memphasys has secured a 12-month exclusive national supply agreement with Monash IVF for its Felix sperm selection system.

Seja Al Zaidi

4 days ago

ASX News Healthcare Biotechnology

Paradigm Biopharmaceuticals has completed enrolment in its pivotal Phase 3 osteoarthritis trial, with top-line results due in early 2027.

Seja Al Zaidi

5 days ago

ASX News Healthcare Biotechnology

Memphasys has signed an exclusive agreement with TMSC Vietnam for the sale and distribution of its unique Felix System.

Colin Sandell-Hay

01 Jun 2026 12:40 (AEST)

ASX News Healthcare Biotechnology

Memphasys continues to expand the global market for its Felix system with new orders from the Middle East and North Africa (MENA) region.

Colin Sandell-Hay

27 May 2026 11:22 (AEST)

ASX News Healthcare Biotechnology

Noxopharm has obtained new data showing how the Sofra technology platform will be leveraged to fight cancer.

Colin Sandell-Hay

26 May 2026 14:26 (AEST)

ASX News Healthcare Biotechnology

Island Pharmaceuticals has made a key appointment ahead of US biodefence trials and dose optimisation studies.

Colin Sandell-Hay

19 May 2026 16:23 (AEST)

ASX News Healthcare Biotechnology

Amplia Therapeutics and the ANZOG have entered into an agreement to conduct a new clinical study into ovarian cancer.

Colin Sandell-Hay

08 May 2026 14:28 (AEST)

ASX News Healthcare Biotechnology

Preparations underway for US FDA pre-IND meeting Move to boost SOF-SKN treatment commercial potential Global clinical research organisation signed Global CLE market is worth more than US$3.3 billion andClinical-stage Australian biotech company Noxopharm (ASX:NOX) has engaged a global cli...

Colin Sandell-Hay

06 May 2026 11:02 (AEST)

ASX News Healthcare Biotechnology

Paradigm Biopharma's pivotal Phase 3 PARA_OA_012 clinical trial will "proceed as designed" after a safety review went off without a hitch.

Isaac McIntyre

30 Apr 2026 09:31 (AEST)

ASX News Healthcare Biotechnology

Biome Australia has filed its inaugural patent application for proprietary next generation probiotic strain BMB18.

Colin Sandell-Hay

27 Apr 2026 13:44 (AEST)

ASX News Healthcare Biotechnology

Paradigm Biopharma (ASX:PAR) has this week hit two big items out the park: first of all, hitting 50% recruitment in its Phase III osteoarthritis (OA) trial using iPPS, which allows the company to post interim efficacy data around August. Listen to the HotCopper podcast for in-depth discussions an...

Jonathon Davidson

02 Apr 2026 15:13 (AEDT)

ASX News Healthcare Biotechnology

Paradigm Biopharma has officially passed a milestone that gives investors in the company a 'fast-track' path to topline data.

Jonathon Davidson

31 Mar 2026 12:03 (AEDT)

ASX News Healthcare Biotechnology

Biotechnology News

Paradigm Biopharma completes enrolment in pivotal Phase 3 osteoarthritis trial

Memphasys lands national Monash IVF supply deal for Felix system

Paradigm clears key Phase 3 hurdle as osteoarthritis trial enrolment completes

Memphasys inks maiden South-East Asian commercialisation agreement

Memphasys receives order for 1000 Felix cartridges across MENA markets

Noxopharm leaps on confirmation of cancer-fighting potential with new Sofra data

Island Pharmaceuticals makes key appointment ahead of US biodefence trials

Amplia Therapeutics and ANZGOG to undertake ovarian cancer study

Noxopharm brings in specialist support to help progress its US regulatory strategy

Paradigm Biopharma advances Phase 3 OA Trial on tail of positive DSMB safety review

Biome Australia files first patent application for probiotic strain

With osteo Phase 3 trial at 50% recruitment, Paradigm Bio inks partnership with University of London

Investors will get interim results from Paradigm's Phase III study in Q3 of this year